Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Tao Xie

TitleAssociate Professor
InstitutionUniversity of Chicago
DepartmentNeurology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Tao Xie, MD, PhD, specializes in the diagnosis and treatment of various movement disorders, including Parkinson's disease, progressive supranuclear palsy (PSP), multiple system atrophy (MSA), cortical basal ganglionic degeneration (CBGD), Huntington's disease (HD) and chorea, tremor, dystonia, hemifacial spasm, blepharospasm, tics, and Tourette syndrome. He uses medications, botulinum toxin injection and deep brain stimulation surgery for treatment of these neurological conditions.

    In his clinical research, Dr. Xie studies the effectiveness of deep brain stimulation for the treatment of various movement disorders. He is also actively involved in clinical trials and research in Parkinson’s disease, PSP, MSA and tremor, and also the role of the DatScan in movement disorders.

    Dr. Xie is a physician in the University of Chicago Center for Parkinson's Disease and Movement Disorders. Dedicated as a Center for Advanced Research by the American Parkinson Disease Association, this multidisciplinary center combines clinical expertise with state-of-the-art therapies and groundbreaking research.


    Collapse Biography 
    Collapse education and training
    Columbia University Medical Center, NYFellowshipMovement Disorders
    Emory University School of Medicine, GAResidency
    Emory University School of Medicine, GAInternship
    Johns Hopkins School of Medicine, MDResearch
    The University of Hong KongPh.D.Parkinson's Disease
    Zhejiang University School of Medicine, ChinaMD

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Vollstedt EJ, Kasten M, Klein C. Using global team science to identify genetic parkinson's disease worldwide. Ann Neurol. 2019 Aug; 86(2):153-157. PMID: 31155756.
      View in: PubMed
    2. Luo L, Andrews H, Alcalay RN, Poyraz FC, Boehme AK, Goldman JG, Xie T, Tuite P, Henchcliffe C, Hogarth P, Amara AW, Frank S, Sutherland M, Kopil C, Naito A, Kang UJ. Motor phenotype classification in moderate to advanced PD in BioFIND study. Parkinsonism Relat Disord. 2019 Jun 23. PMID: 31255537.
      View in: PubMed
    3. Miterko LN, Baker KB, Beckinghausen J, Bradnam LV, Cheng MY, Cooperrider J, DeLong MR, Gornati SV, Hallett M, Heck DH, Hoebeek FE, Kouzani AZ, Kuo SH, Louis ED, Machado A, Manto M, McCambridge AB, Nitsche MA, Taib NOB, Popa T, Tanaka M, Timmann D, Steinberg GK, Wang EH, Wichmann T, Xie T, Sillitoe RV. Consensus Paper: Experimental Neurostimulation of the Cerebellum. Cerebellum. 2019 Jun 04. PMID: 31165428.
      View in: PubMed
    4. Boxer AL, Qureshi I, Ahlijanian M, Grundman M, Golbe LI, Litvan I, Honig LS, Tuite P, McFarland NR, O'Suilleabhain P, Xie T, Tirucherai GS, Bechtold C, Bordelon Y, Geldmacher DS, Grossman M, Isaacson S, Zesiewicz T, Olsson T, Muralidharan KK, Graham DL, O'Gorman J, Haeberlein SB, Dam T. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019 Jun; 18(6):549-558. PMID: 31122495.
      View in: PubMed
    5. Brittain C, McCarthy A, Irizarry MC, McDermott D, Biglan K, Höglinger GU, Lorenzl S, Del Ser T, Boxer AL. Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism Relat Disord. 2019 Mar; 60:138-145. PMID: 30201421.
      View in: PubMed
    6. Xie T, Bloom L, Padmanaban M, Bertacchi B, Kang W, MacCracken E, Dachman A, Vigil J, Satzer D, Zadikoff C, Markopoulou K, Warnke P, Kang UJ. Long-term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD. J Neurol Neurosurg Psychiatry. 2018 Sep; 89(9):989-994. PMID: 29654112.
      View in: PubMed
    7. Rojas JC, Bang J, Lobach IV, Tsai RM, Rabinovici GD, Miller BL, Boxer AL. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2018 01 23; 90(4):e273-e281. PMID: 29282336.
      View in: PubMed
    8. Goldman JG, Andrews H, Amara A, Naito A, Alcalay RN, Shaw LM, Taylor P, Xie T, Tuite P, Henchcliffe C, Hogarth P, Frank S, Saint-Hilaire MH, Frasier M, Arnedo V, Reimer AN, Sutherland M, Swanson-Fischer C, Gwinn K. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Mov Disord. 2018 02; 33(2):282-288. PMID: 29205509.
      View in: PubMed
    9. Xie T, Padmanaban M, Bloom L, MacCracken E, Bertacchi B, Dachman A, Warnke P. Effect of low versus high frequency stimulation on freezing of gait and other axial symptoms in Parkinson patients with bilateral STN DBS: a mini-review. Transl Neurodegener. 2017; 6:13. PMID: 28529730.
      View in: PubMed
    10. Pirio Richardson S, Wegele AR, Skipper B, Deligtisch A, Jinnah HA. Dystonia treatment: Patterns of medication use in an international cohort. Neurology. 2017 Feb 07; 88(6):543-550. PMID: 28077492.
      View in: PubMed
    11. Xie T, Kang UJ. Comments on the recent viewpoint article on low-frequency deep brain stimulation for Parkinson's disease. Mov Disord. 2017 01; 32(1):176. PMID: 27862290.
      View in: PubMed
    12. Norris SA, Jinnah HA, Espay AJ, Klein C, Brüggemann N, Barbano RL, Malaty IA, Rodriguez RL, Vidailhet M, Roze E, Reich SG, Berman BD, LeDoux MS, Richardson SP, Agarwal P, Mari Z, Ondo WG, Shih LC, Fox SH, Berardelli A, Testa CM, Cheng FC, Truong D, Nahab FB, Xie T, Hallett M, Rosen AR, Wright LJ, Perlmutter JS. Clinical and demographic characteristics related to onset site and spread of cervical dystonia. Mov Disord. 2016 12; 31(12):1874-1882. PMID: 27753188.
      View in: PubMed
    13. Dutt S, Binney RJ, Heuer HW, Luong P, Attygalle S, Bhatt P, Marx GA, Elofson J, Tartaglia MC, Litvan I, McGinnis SM, Dickerson BC, Kornak J, Waltzman D, Voltarelli L, Schuff N, Rabinovici GD, Kramer JH, Jack CR, Miller BL, Rosen HJ, Boxer AL. Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology. 2016 Nov 08; 87(19):2016-2025. PMID: 27742814.
      View in: PubMed
    14. Xie T, Appelbaum D, Bernard J, Padmanaban M, Pu Y, Gomez C. Evaluation of parkinsonism and striatal dopamine transporter loss in patients with spinocerebellar ataxia type 6. J Neurol. 2016 Nov; 263(11):2302-2307. PMID: 27544504.
      View in: PubMed
    15. Kang UJ, Goldman JG, Alcalay RN, Xie T, Tuite P, Henchcliffe C, Hogarth P, Amara AW, Frank S, Rudolph A, Casaceli C, Andrews H, Gwinn K, Sutherland M, Kopil C, Vincent L, Frasier M. The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. Mov Disord. 2016 06; 31(6):924-32. PMID: 27113479.
      View in: PubMed
    16. Xie T, Vigil J, MacCracken E, Warnke P, Kang UJ. Author Response. Neurology. 2015 Aug 11; 85(6):557. PMID: 26484368.
      View in: PubMed
    17. Xie T, Guan R, Staisch J, Towle VL, Warnke P. Respiratory dyskinesia in a patient with Parkinson disease successfully treated with STN DBS. Neurology. 2015 Aug 04; 85(5):479-80. PMID: 26138944.
      View in: PubMed
    18. Xie T, Kang UJ, Kuo SH, Poulopoulos M, Greene P, Fahn S. Comparison of clinical features in pathologically confirmed PSP and MSA patients followed at a tertiary center. NPJ Parkinsons Dis. 2015; 1:15007. PMID: 28725681.
      View in: PubMed
    19. Xie T, Vigil J, MacCracken E, Gasparaitis A, Young J, Kang W, Bernard J, Warnke P, Kang UJ. Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. Neurology. 2015 Jan 27; 84(4):415-20. PMID: 25540305.
      View in: PubMed
    20. Rydz D, Lin CY, Xie T, Cortes E, Vonsattel JP, Kuo SH. Pathological findings of anti-Yo cerebellar degeneration with Holmes tremor. J Neurol Neurosurg Psychiatry. 2015 Jan; 86(1):121-2. PMID: 24876186.
      View in: PubMed
    21. Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, Roberson ED, Höglinger GU, Koestler M, Jack CR, Van Deerlin V, Randolph C, Lobach IV, Heuer HW, Gozes I, Parker L, Whitaker S, Hirman J, Stewart AJ, Gold M, Morimoto BH. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul; 13(7):676-85. PMID: 24873720.
      View in: PubMed
    22. Xie T, Awad I, Kang UJ, Warnke P. DBS reduced hemichorea associated with a developmental venous anomaly and microbleeding in STN. Neurology. 2014 Feb 18; 82(7):636-7. PMID: 24384639.
      View in: PubMed
    23. Kuo SH, Xie T, Fahn S. Anticholinergic responsive cyclic myoclonus. Mov Disord. 2013 Mar; 28(3):401-2. PMID: 23404345.
      View in: PubMed
    24. Xie T, Bernard J, Warnke P. Post subthalamic area deep brain stimulation for tremors: a mini-review. Transl Neurodegener. 2012 Oct 29; 1(1):20. PMID: 23210767.
      View in: PubMed
    25. Xie T, Warnke P, Kang UJ, de la Fuente-Fernandez R. Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology. 2012 Oct 16; 79(16):1744; author reply 1744. PMID: 23071169.
      View in: PubMed
    26. Kang UJ, Xie T. Diagnostic biomarkers of Parkinson's disease: what gain at what cost? J Neurol Neurosurg Psychiatry. 2012 Aug; 83(8):769. PMID: 22733084.
      View in: PubMed
    27. Xie T, Kang UJ, Warnke P. Effect of stimulation frequency on immediate freezing of gait in newly activated STN DBS in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2012 Oct; 83(10):1015-7. PMID: 22696586.
      View in: PubMed
    28. Xie T, Goodman R, Browner N, Haberfeld E, Winfield L, Goldman J, Ford B. Treatment of fragile X-associated tremor/ataxia syndrome with unilateral deep brain stimulation. Mov Disord. 2012 May; 27(6):799-800. PMID: 22344717.
      View in: PubMed
    29. Xie T, Tong L, McLane MW, Hatzidimitriou G, Yuan J, McCann U, Ricaurte G. Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. Neuropsychopharmacology. 2006 Dec; 31(12):2639-51. PMID: 16452989.
      View in: PubMed
    30. Liu J, Huang Q, Higdon J, Liu W, Xie T, Yamashita T, Cheon K, Cheng C, Zuo J. Distinct gene expression profiles and reduced JNK signaling in retinitis pigmentosa caused by RP1 mutations. Hum Mol Genet. 2005 Oct 01; 14(19):2945-58. PMID: 16126734.
      View in: PubMed
    31. Ricaurte GA, Mechan AO, Yuan J, Hatzidimitriou G, Xie T, Mayne AH, McCann UD. Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates. J Pharmacol Exp Ther. 2005 Oct; 315(1):91-8. PMID: 16014752.
      View in: PubMed
    32. Xie T, Tong L, McCann UD, Yuan J, Becker KG, Mechan AO, Cheadle C, Donovan DM, Ricaurte GA. Identification and characterization of metallothionein-1 and -2 gene expression in the context of (+/-)3,4-methylenedioxymethamphetamine-induced toxicity to brain dopaminergic neurons. J Neurosci. 2004 Aug 11; 24(32):7043-50. PMID: 15306638.
      View in: PubMed
    33. Jiang H, Xie T, Ramsden DB, Ho SL. Human catechol-O-methyltransferase down-regulation by estradiol. Neuropharmacology. 2003 Dec; 45(7):1011-8. PMID: 14573393.
      View in: PubMed
    34. Xie T, Tong L, Barrett T, Yuan J, Hatzidimitriou G, McCann UD, Becker KG, Donovan DM, Ricaurte GA. Changes in gene expression linked to methamphetamine-induced dopaminergic neurotoxicity. J Neurosci. 2002 Jan 01; 22(1):274-83. PMID: 11756511.
      View in: PubMed
    35. Barrett T, Xie T, Piao Y, Dillon-Carter O, Kargul GJ, Lim MK, Chrest FJ, Wersto R, Rowley DL, Juhaszova M, Zhou L, Vawter MP, Becker KG, Cheadle C, Wood WH, McCann UD, Freed WJ, Ko MS, Ricaurte GA, Donovan DM. A murine dopamine neuron-specific cDNA library and microarray: increased COX1 expression during methamphetamine neurotoxicity. Neurobiol Dis. 2001 Oct; 8(5):822-33. PMID: 11592851.
      View in: PubMed
    36. Ramsden DB, Parsons RB, Ho SL, Xie T, Waring RH, Williams AC. Further studies in xenobiotic metabolism and Parkinson's disease. Adv Neurol. 2001; 86:105-13. PMID: 11553967.
      View in: PubMed
    37. Xie T, McCann UD, Kim S, Yuan J, Ricaurte GA. Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity. J Neurosci. 2000 Oct 15; 20(20):7838-45. PMID: 11027249.
      View in: PubMed
    38. Xie T, Ho SL, Ramsden D. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol Pharmacol. 1999 Jul; 56(1):31-8. PMID: 10385681.
      View in: PubMed
    39. Hong J, Shu-Leong H, Tao X, Lap-Ping Y. Distribution of catechol-O-methyltransferase expression in human central nervous system. Neuroreport. 1998 Aug 24; 9(12):2861-4. PMID: 9760135.
      View in: PubMed
    40. Xie T, Ho SL, Ramsden D. Catechol-O-methyltransferase inhibitors in Parkinson's disease. Lancet. 1998 Jun 27; 351(9120):1966. PMID: 9654300.
      View in: PubMed
    41. Xie T, Ho SL, Ma OC. High resolution single strand conformation polymorphism analysis using formamide and ethidium bromide staining. Mol Pathol. 1997 Oct; 50(5):276-8. PMID: 9497922.
      View in: PubMed
    42. Xie T, Ho SL, Li LS, Ma OC. G/A1947 polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's disease. Mov Disord. 1997 May; 12(3):426-7. PMID: 9159741.
      View in: PubMed
    Xie's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (212) concept(s)
    _
    Co-Authors Expand Description
    See all (10) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department
    Physical Neighbors Expand Description
    _